www射-国产免费一级-欧美福利-亚洲成人福利-成人一区在线观看-亚州成人

Global EditionASIA 中文雙語Fran?ais
Business
Home / Business / Companies

AstraZeneca gives rare diseases new challenge

By ZHOU WENTING in Shanghai | China Daily | Updated: 2023-03-02 09:29
Share
Share - WeChat
Visitors gather at AstraZeneca's booth during the fifth China International Import Expo in Shanghai in November. [Photo/China Daily]

United Kingdom-based global pharmaceutical company AstraZeneca has integrated more than 10 molecular products worldwide in the rare diseases field and is promoting more than 20 clinical research programs, said an executive of the company.

The company will continue to introduce new product portfolios over the upcoming five years after announcing joining the rare diseases realm in 2021, said Hu Yiqing, vice-president of AstraZeneca China and head of its rare diseases business unit, in an interview with China Daily ahead of the International Rare Diseases Day, which fell on Tuesday this year.

Areas of focus will include hematology, nephrology, neurology, metabolic disorders and ophthalmology, she said.

"In addition to the acquisition of Alexion, which specializes in rare disease therapies, in 2020, AstraZeneca announced the acquisition of LogicBio Therapeutics, which had a leading position in the development of gene delivery and gene editing and was committed to tackling various rare and serious diseases afflicting children and adults," said Hu.

"Therefore, the company will expand its layout of rare diseases at the level of genomics," she said.

In terms of research and development in the company's rare diseases therapy catalog, Hu said China and the rest of the world are developing at the same time.

"In addition to the introduction of innovative medicines that have entered the markets overseas to China, all the therapies that are under research progress will be promoted into clinical trials in China simultaneously," she said.

In November, China approved the first rare disease therapy from AstraZeneca, bringing innovative treatment options to paroxysmal nocturnal hemoglobinuria and atypical hemolytic-uremic syndrome, two diseases related to kidney and blood vessel malfunctions in adults and children.

The company is pushing forward the therapy's approval for other new indications and the approval for another medicine to treat a rare neurofibroma, a neurological condition, to benefit more patients, said Hu.

Data from market research firm Frost & Sullivan showed that the size of the rare disease treatment market in China is expected to surge from $1.3 billion in 2020 to $25.9 billion in 2030 with a compound annual growth rate of 34.5 percent. Experts believe that it is a result of the actual needs of the patients.

The country has unveiled favorable measures to streamline a new medicine market used in the rare disease field. Some therapies with clinical data overseas can register without clinical data domestically to accelerate foreign innovative drugs being brought into the country, according to experts.

Besides acceleration in bringing new therapies, Hu said the company will also contribute to building a more complete diagnosis and treatment system regarding rare diseases.

The country has established a collaboration network of rare diseases among hospitals nationwide and 60 of them were designated as medical centers. Hu said AstraZeneca will help strengthen multidisciplinary treatment capability at the medical centers as rare diseases are usually diagnosed jointly by doctors from various backgrounds.

"These medical centers will later expand their practice and standardize diagnosis and treatment of relevant diseases at other medical institutions. Also, the hospitals will build transfer mechanisms for high-risk patients," said Hu.

Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
CLOSE
 
主站蜘蛛池模板: 免费观看一级特黄欧美大片 | 一级一黄在线观看视频免费 | 欧美日韩一区二区三区四区在线观看 | 欧美一区二区三区免费播放 | 香港三级日本三级人妇三级四 | 亚洲欧洲精品国产二码 | 成年女人在线观看片免费视频 | 香蕉超级碰碰碰97视频蜜芽 | 91精品欧美一区二区综合在线 | 亚洲精品人成网线在线 | 99精品久久久久久久 | 亚洲一区二区在线免费观看 | 永久毛片| 日本在线视频免费看 | www女人| 色噜噜国产精品视频一区二区 | 国产精品一二区 | 性精品| 免费黄色在线网址 | 欧美videosex性欧美成人 | 亚洲一区二区免费看 | 农村寡妇野外情一级毛片 | 免费人成在线 | 欧美真人毛片动作视频 | 操爽视频 | 精品午夜寂寞影院在线观看 | 亚洲第一区精品日韩在线播放 | 色午夜在线 | 亚洲资源在线播放 | 欧美日韩第二页 | 欧美成人看片黄a免费 | 老王午夜69精品影院 | 国产另类视频 | 欧美一级一毛片 | 久久er国产精品免费观看1 | 三级黄色a| 国产精品分类视频分类一区 | 国产精品反差婊在线观看 | 精品久久久日韩精品成人 | 8888奇米四色在线 | 97在线视频免费公开观看 |